People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head ... Other factors can affect access. This week, CVS Health ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

The Trump administration’s Monday executive order could restructure how Americans buy prescription drugs, pushing them away ...